Your browser version may not work well with NCBI's Web applications. More information here...
Items 1 - 20 of 292
of 15Next
1:

Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.

Tan AY, Westerman DA, Carney DA, Seymour JF, Juneja S, Dobrovic A.

J Hematol Oncol. 2008 Jul 29;1:10.

PMID: 18664261 [PubMed - in process]

2:

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.

Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, Fricke HJ, Höffken K, Wedding U.

Eur J Haematol. 2008 Mar;80(3):208-15.

PMID: 18081718 [PubMed - indexed for MEDLINE]

3:

[A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia]

Wu DP, Yan LZ, Yang L, Chen SN, Wu XJ, Liang JY.

Zhonghua Nei Ke Za Zhi. 2007 Nov;46(11):907-10. Chinese.

PMID: 18261272 [PubMed - indexed for MEDLINE]

4:

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G.

Blood. 2006 May 15;107(10):4011-20. Epub 2006 Feb 2.

PMID: 16455956 [PubMed - indexed for MEDLINE]

5:

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

PMID: 15746041 [PubMed - indexed for MEDLINE]

6:

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B.

Blood. 2005 Dec 1;106(12):3733-9. Epub 2005 Aug 2.

PMID: 16076867 [PubMed - indexed for MEDLINE]

7:

Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.

Suzuki R, Onizuka M, Kojima M, Shimada M, Okamura K, Fukagawa S, Tsuboi K, Kikuchi A, Kobayashi H, Shintani A, Ogawa Y, Kawada H, Hotta T, Ando K.

Int J Hematol. 2007 Dec;86(5):422-8.

PMID: 18192111 [PubMed - indexed for MEDLINE]

8:

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H.

Blood. 2005 Dec 1;106(12):3740-6. Epub 2005 Jul 28.

PMID: 16051734 [PubMed - indexed for MEDLINE]

9:

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD.

J Clin Oncol. 2008 Oct 1;26(28):4595-602. Epub 2008 Jun 16.

PMID: 18559874 [PubMed - indexed for MEDLINE]

10:

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

N Engl J Med. 2008 May 1;358(18):1909-18.

PMID: 18450602 [PubMed - indexed for MEDLINE]

11:

Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.

Mori Y, Yoshimoto G, Kumano T, Miyamoto T, Iino T, Takenaka K, Iwasaki H, Harada N, Kinukawa N, Nagafuji K, Teshima T, Shimoda K, Akashi K, Harada M.

Eur J Haematol. 2007 Jul;79(1):17-24.

PMID: 17598835 [PubMed - indexed for MEDLINE]

12:

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC; Medical Research Council Adult Leukaemia Working Party.

Blood. 2008 Mar 1;111(5):2776-84. Epub 2007 Oct 23.

PMID: 17957027 [PubMed - indexed for MEDLINE]

13:

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrózek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B Study.

J Clin Oncol. 2007 Aug 1;25(22):3337-43. Epub 2007 Jun 18.

PMID: 17577018 [PubMed - indexed for MEDLINE]

14:

Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.

Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F, Amadori S, Mecucci C, Falini B, Lo-Coco F.

Leukemia. 2005 Aug;19(8):1479-82. Erratum in: Leukemia. 2007 May;21(5):1134.

PMID: 15973451 [PubMed - indexed for MEDLINE]

15:

Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations.

Boonthimat C, Thongnoppakhun W, Auewarakul CU.

Haematologica. 2008 Oct;93(10):1565-9. Epub 2008 Jul 18.

PMID: 18641025 [PubMed - in process]

16:

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B, Valk PJ.

Blood. 2005 Dec 1;106(12):3747-54. Epub 2005 Aug 18.

PMID: 16109776 [PubMed - indexed for MEDLINE]

17:

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H; German-Austrian AML Study Group (AMLSG).

Haematologica. 2009 Jan;94(1):54-60. Epub 2008 Dec 4.

PMID: 19059939 [PubMed - in process]

18:

Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.

Colovic N, Tosic N, Aveic S, Djuric M, Milic N, Bumbasirevic V, Colovic M, Pavlovic S.

Ann Hematol. 2007 Oct;86(10):741-7. Epub 2007 Jun 20.

PMID: 17579862 [PubMed - indexed for MEDLINE]

19:

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T.

Blood. 2005 Oct 15;106(8):2854-61. Epub 2005 Jun 30.

PMID: 15994285 [PubMed - indexed for MEDLINE]

20:

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

Bianchini M, Ottaviani E, Grafone T, Giannini B, Soverini S, Terragna C, Amabile M, Piccaluga PP, Malagola M, Rondoni M, Bosi C, Baccarani M, Martinelli G.

Clin Chem. 2003 Oct;49(10):1642-50.

PMID: 14500589 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 292
of 15Next